Abbott reports positive data from XIENCE Short DAPT programme
Abbott has reported positive data from two trials in its XIENCE Short dual antiplatelet therapy (DAPT) programme. Credit: Abbott.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more